Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 2
1995 5
1996 4
1997 5
1998 10
1999 14
2000 29
2001 18
2002 23
2003 26
2004 16
2005 18
2006 16
2007 19
2008 13
2009 20
2010 18
2011 9
2012 7
2013 11
2014 7
2015 3
2016 1
2017 7
2018 5
2019 7
2020 6
2021 9
2022 5
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 16220085

325 results

Results by year

Filters applied: . Clear all
Page 1
Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
Krogstad P, Lee S, Johnson G, Stanley K, McNamara J, Moye J, Jackson JB, Aguayo R, Dieudonne A, Khoury M, Mendez H, Nachman S, Wiznia A; Pediatric AIDS Clinical Trials Group 377 Study Team. Krogstad P, et al. Clin Infect Dis. 2002 Apr 1;34(7):991-1001. doi: 10.1086/338814. Epub 2002 Feb 27. Clin Infect Dis. 2002. PMID: 11880966 Clinical Trial.
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
Eshleman SH, Krogstad P, Jackson JB, Wang YG, Lee S, Wei LJ, Cunningham S, Wantman M, Wiznia A, Johnson G, Nachman S, Palumbo P. Eshleman SH, et al. J Infect Dis. 2001 Jun 15;183(12):1732-8. doi: 10.1086/320728. Epub 2001 May 16. J Infect Dis. 2001. PMID: 11372025 Clinical Trial.
A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.
Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG, Williams VC, Shaefer MS, Pakes GE, Pappa KA; ESS40002 Study Team. Kumar PN, et al. HIV Med. 2006 Mar;7(2):85-98. doi: 10.1111/j.1468-1293.2006.00346.x. HIV Med. 2006. PMID: 16420253 Free article. Clinical Trial.
Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team.
Wiznia A, Stanley K, Krogstad P, Johnson G, Lee S, McNamara J, Moye J, Jackson JB, Mendez H, Aguayo R, Dieudonne A, Kovacs A, Bamji M, Abrams E, Rana S, Sever J, Nachman S. Wiznia A, et al. AIDS Res Hum Retroviruses. 2000 Aug 10;16(12):1113-21. doi: 10.1089/088922200414956. AIDS Res Hum Retroviruses. 2000. PMID: 10954886 Clinical Trial.
Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
Lowe SH, Wensing AM, Hassink EA, ten Kate RW, Richter C, Schreij G, Koopmans PP, Juttmann JR, van der Tweel I, Lange JM, Borleffs JC. Lowe SH, et al. HIV Clin Trials. 2005 Sep-Oct;6(5):235-45. doi: 10.1310/A686-M37Y-J2PT-E9GJ. HIV Clin Trials. 2005. PMID: 16306030 Clinical Trial.
325 results